TFS expert Mesfin James highlights Europe’s clinical development strengths and regulatory shifts creating new sponsor opportunities.
Read More
TFS HealthScience achieves a B score in the 2025 CDP Climate Change assessment, demonstrating strengthened climate governance and responsible CRO practices.
TFS expands its global neuroscience portfolio, strengthening its gene therapy expertise across neurodegenerative diseases through innovation & collaboration.
TFS shares ESG progress in its 2024 Sustainability Report, highlighting emissions cuts and a global commitment to people and the planet.
Recognition highlights the CRO’s global expansion strategy, sponsor-focused execution, and commitment to operational excellence. LUND, S.E., May 14, 2025 – TFS HealthScience (TFS), a leading global Contract Research Organization (CRO),…
LUND, S.E., May 6, 2025 – TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is deepening its collaboration with Oncomatryx, a biopharmaceutical company developing novel antibody-drug conjugates (ADCs)…
LUND, S.E., April 29, 2025 – TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is advancing the next phase of its strategic growth journey under CEO Markus Granlund….
LUND, S.E., April 2, 2025 – TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), announces continued advancement in its sustainability journey, marked by a strengthened assessment from CDP, formerly the Carbon Disclosure Project.